Premium Alternative Insight and Premium Journalism

The Latest
Hedge funds specializing in fledgling biopharma and health care companies have experienced wide variation in performance this year.
The Tiger Grandcub is easily outperforming its Tiger peers and other hedge funds.
The multistrategy hedge fund’s equity strategy led the way last month, kicking in 5.2 percent to net returns.
This retailing giant enjoyed a surge of hedge fund buying in the first quarter.
After facing a challenging fundraising environment for the new fund in 2022, Mudrick has lowered its target.
It was feast or famine for most of David Einhorn’s largest longs last month.
A slew of new hedgies initiated positions in this semiconductor company.
More in Premium